Stocks · News reference
Benchmark Maintains Speculative Buy on Humacyte, Lowers Price Target to $1
Benchmark analyst Bruce D. Jackson maintains Humacyte (NASDAQ:HUMA) with a Speculative Buy and lowers the price target from $2 to $1.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 13, 2026, 1:26 PM
- Checked
- Aug 13, 2026, 1:26 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Humacyte shares are trading higher after the company announced the publication of one-year Phase 3 results of its acellular tissue engineered vessel for hemodialysis access in The Lancet Digital Health.
Read original at benzingaHumacyte Announces Publication Of One-Year V007 Phase 3 Results In The Lancet Digital Health Showing ATEV Superiority Over Autogenous Fistula For Hemodialysis Access
Read original at benzingaHumacyte Announces Symvess Acellular Tissue Engineered Vessel-Tyod Now Being Used By Arizona Surgeons
Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology company that develops bioengineered human tissues, today announced that Symvess, acellular tissue engineered vessel-tyod, is now being used by surgeons in
Read original at benzinga